New facility in The Woodlands, TX accelerates Cellipont’s cell therapy innovation
Cellipont Bioservices (Cellipont), a cell therapy contract development and manufacturing organization (CDMO), announced a strategic debt facility investment from OrbiMed, a healthcare investment firm. The investment will be used by Cellipont to fully finance the previously announced state-of-the-art commercial facility for cell therapies and gene-modified cell therapies in The Woodlands, Texas.
“This expansion underscores our unwavering commitment to going above and beyond for our clients and patients”
“We are energized by this partnership with OrbiMed, which helps us to bring this world-class facility to completion in 2023,” said Deborah Wild, President and CEO of Cellipont. “Once completed, Cellipont will be uniquely positioned to offer technically-superior, highly-responsive outsourced contract development and GMP manufacturing services to innovative cell therapy companies. OrbiMed understands our vision, has a unique portfolio of life science companies, and was the ideal partner for Cellipont in this journey.”
The 76,000-square-foot facility will feature significant capabilities including process and analytical development (PD/AD) and manufacturing services for CAR-T, IPSC, MSC and other types of cell therapies. OrbiMed’s support will enable clients to take advantage of cutting-edge cleanrooms, promising technological innovations, and a team with deep scientific expertise in a best-in-class facility.
Matthew Rizzo, General Partner of OrbiMed, commented “OrbiMed is excited to partner with Cellipont for their continued growth. Cellipont’s scientific expertise, state-of-the-art facilities, and unique capabilities were apparent to us throughout our debt process and we believe the Company is well prepared to capitalize on future demand as the cell and gene therapy CDMO market continues to grow and evolve.”
The new complex, which broke ground in November 2022, is specially designed to meet Cellipont’s agile manufacturing style that marries technical excellence and personal service to help clients get to target endpoints faster.
“This expansion underscores our unwavering commitment to going above and beyond for our clients and patients,” said Darren Head, Chairman of Cellipont. “We look forward to accelerating cell therapy innovation by offering our partners state-of-the-art facilities with the power to unlock life-changing medicines.”
Cellipont first announced plans to develop the new facility in August 2022, with construction set to be completed in several phases. The firm recently added two experienced executives to its commercial leadership team, hiring Brian Walsh as Senior Vice President of Business Development and Aaron Solis as Senior Director of Business Development. Cellipont also recently hired Tim Heher as CFO, who possesses extensive experience operating private equity backed CDMO investments. OrbiMed now teams up with existing financial sponsor, Great Point Partners, who first partnered with Cellipont in 2021.
Cision distribution by PR Newswire empowers communicators to identify and engage with key influencers, craft and distribute meaningful stories, and measure the financial impact of their efforts. Cision is a leading global provider of earned media software and services to public relations and marketing communications professionals.